The phase III randomized clinical trial KEYNOTE-062 evaluated the efficacy and safety of first-line treatment in patients with untreated, advanced gastric/GEJ (G/GEJ) cancer with a PD-L1 CPS of ≥ 1 (Table 1). Here, CD274 is linked to cancer.